Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.

ABSTRACT:

Background

Antifungal prophylaxis (AFP) reduces the incidence of invasive fungal infections (IFIs) during induction therapy of acute myeloid leukemia (AML). Posaconazole is considered the standard of care. Voriconazole, a generic cheaper alternative is a newer generation azole with broad anti-fungal activity. There is limited data on the use of voriconazole as a prophylactic drug.

Materials and methods

A single-center, prospective study was performed during which patients with AML undergoing induction chemotherapy received voriconazole as AFP (April 2012 to February 2014). Outcomes were compared with historical patients who received fluconazole as AFP (January 2011-March 2012, n = 66).

Results

Seventy-five patients with AML (median age: 17 years [range: 1-75]; male:fe

SUBMITTER: Shah A 

PROVIDER: S-EPMC4795377 | biostudies-literature | 2016 Jan-Mar

REPOSITORIES: biostudies-literature